Mood in Parkinson's Disease
Mood in Parkinson's Disease
Embedded Files
Mood symptoms, including depression, anxiety, and apathy, are prevalent and multifaceted in Parkinson's disease. A comprehensive approach is imperative for their management, encompassing both the neurobiological aspects of the disease itself and the impact of motor therapies. The panel's clinical experience with Safinamide has yielded novel insights for addressing these symptoms, attributable to its multimodal action profile that extends beyond the dopaminergic system.
Treatment Prior to Safinamide
Treatment Prior to Safinamide
Prior to the advent of Safinamide, the therapeutic management of mood disorders was predicated on a plethora of pharmaceutical agents targeting discrete symptoms, with a substantial reliance on conventional antidepressants and anxiolytics.
During the discussion, the panel expressed mounting concern regarding the utilization of pramipexole for depression, citing evidence that suggests a potential association with the subsequent development of apathy. This has prompted a re-evaluation of its role in this context.
Adoption and clinical experience with Safinamide for mood disorders
Adoption and clinical experience with Safinamide for mood disorders
According to experts in the field, the utilization of Safinamide for the management of mood symptoms in patients exhibiting symptoms of depression and who demonstrate an inadequate response to SSRIs (selective serotonin reuptake inhibitors) or when a multifaceted therapeutic approach targeting both dopaminergic and glutamatergic pathways is pursued, involves the administration of a single medication capable of addressing multiple symptoms, in accordance with the principle of pharmacological optimization.
The benefits that the panel has identified include:
Reduction in depression scales: A notable enhancement has been documented in cases of mild to moderate depression.
Mood stability: Patients have reported a decline in mood fluctuations, which are frequently associated with "OFF" periods.
Impact on quality of life: The collective perception of well-being exhibited a marked enhancement, accompanied by a quantifiable positive influence on quality of life assessments, as evidenced by the PDQ39 and NMSS scales.
Specific benefits: A salient finding is that safinamide has been demonstrated to enhance domains of interest and motivation, exerting a favorable impact on symptoms such as apathy and fatigue.
Furthermore, the panel posits that the probability of serotonin syndrome when administering safinamide concomitantly with other antidepressants is minimal, contingent upon the judicious selection of patients.
Dose impact: 100 mg vs. 50 mg
Dose impact: 100 mg vs. 50 mg
In contrast to the established consensus regarding the management of pain, a similar consensus regarding the optimal dosage for addressing mood symptoms remains elusive. The panel's experience, in conjunction with the studies reviewed, indicates that there are no statistically significant differences between 50 mg and 100 mg for the specified purpose. The determination of the optimal dosage is contingent upon various factors, including the patient's tolerance level and the presence of comorbidities. It has been posited that the glutamatergic effect, which is pertinent to mood modulation, commences at a dosage of 50 mg.
Explanatory note: The following report summarizes the perspectives, comments, and opinions expressed, as well as those reflected in the working matrices, by the panel of specialists during the "I Experts Meeting: Safinamide and Quality of Life (Evidence/Local Experiences)” held in Cartagena, Colombia, on September 13, 2025.
Report abuse